Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Geron Corporation

Robbins Geller Rudman & Dowd LLP (https://www.rgrdlaw.com/cases-geron-corporation-class-action-lawsuit.h ...) today announced that it filed a class action seeking to represent purchasers of Geron Corporation (NASDAQ:GERN) securities during the period between March 19, 2018 and September 26, 2018 (the “Class Period”). This action was filed in the District of New Jersey and is captioned Pfeifer v. Geron Corp., et al., No. 20-cv-02424.

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Geron securities during the Class Period to seek appointment as lead plaintiff in the Geron securities class action lawsuit. A lead plaintiff acts on behalf of all other class members in directing the Geron securities class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Geron securities class action lawsuit. An investor’s ability to share in any potential future recovery of the Geron securities class action lawsuit is not dependent upon serving as lead plaintiff. If you wish to serve as lead plaintiff in the Geron securities class action lawsuit, you must move the Court no later than 60 days from January 23, 2020. If you wish to discuss the Geron securities class action lawsuit or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Brian E. Cochran of Robbins Geller at 800/449-4900 or 619/231-1058, or via e-mail at [e-mail]. You can view a copy of the complaint as filed at https://www.rgrdlaw.com/cases-geron-corporation-class-action-lawsuit.h ....

The Geron securities class action lawsuit charges Geron and certain of its officers with violations of the Securities Exchange Act of 1934. Geron is a clinical-stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, for the treatment of hematologic myeloid malignancies under a collaboration agreement with Janssen Biotech Inc. (“Janssen”). During the Class Period, Janssen was conducting a Phase 2 trial of imetelstat, known as the IMbark study, for the treatment of myelofibrosis, an uncommon type of bone marrow cancer that disrupts the normal production of blood cells, under the supervision of a Joint Steering Committee (“JSC”) consisting of both Geron and Janssen employees. The JSC conducted an internal non-public review of the IMbark study results in March 2018.